AU
UK
CA
NZ
IND
US
argenx reported positive topline results from the Phase 3 ADAPT SERON study evaluating VYVGART® (efgartigimod) in patients with AChR-Ab seronegative generalized myasthenia gravis (gMG). The trial achieved its primary endpoint, with a reported p-value of 0.0068 for improvement on the Myasthenia Gravis Activities of …
Alvotech (NASDAQ: ALVO) and Advanz Pharma Holdco Limited said the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept). The approval is a centralized marketing authorisation that covers all European Economic Area (EEA) countries — the 27 EU member states plus Norway, …
Smith & Nephew plc (NYSE: SNN) received a price target increase from Canaccord Genuity Group, moving to USD 36 from USD 28 while maintaining a Hold rating, according to a recent research note. The revision follows a period of reassessment across the sell-side: HSBC …
Alcon reported second-quarter 2025 results with net sales of approximately $2.6 billion, a 4% increase on a reported basis and 3% in constant currency versus the prior-year quarter. The company posted diluted earnings per share of $0.35 and core diluted EPS of $0.76 for …
ICU Medical (NASDAQ: ICUI) was upgraded tooverweightby Piper Sandler in a Friday report, with aUSD145price target that indicates an estimated17.92%upside from recent levels, according to MarketBeat. The change reflects a more favorable stance on the company’s near-term risk-reward and earnings trajectory within medical supplies …
Ascentage Pharma announced regulatory clearances from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to initiate GLORA-4, a global Phase III registrational study of lisaftoclax in combination with azacitidine for first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS). The …
Evotec SE reported mixed first-half 2025 results, reflecting divergent trends across its businesses and a challenging discovery market. Group revenues declined 5% year over year to GBP371.2 million as Discovery & Preclinical Development (D&PD) revenue decreased 11% to GBP269.0 million, consistent with softer demand …
Shares of Cardinal Health, Inc. (NYSE: CAH) have received a consensus recommendation of “Moderate Buy” from fourteen research firms currently tracking the stock. Out of these, three analysts rate the stock as “Hold,” while eleven have issued “Buy” ratings.
RadNet, Inc. (NASDAQ: RDNT) reported its second-quarter 2025 financial results, posting record revenue and adjusted earnings. Total revenue for the quarter reached USD 498.2 million, an 8.4% increase from USD 459.8 million in Q2 2024. Adjusted EBITDA rose 12.3% to USD 81.2 million, with …
JPMorgan Chase & Co. has increased its price target for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from USD348.00 to USD475.00, according to a report released Wednesday. The firm maintained an “overweight” rating, indicating expectations for further gains from the company’s latest closing price of USD428.14.
Please wait processing your request...